<p>Identifying predictive and resistance biomarkers remains one of the most relevant unmet needs in clinical cancer research. Artificial Intelligence (AI) represents a powerful tool to develop predictive algorithms tailored to individual patients. Thanks to its ability to process large quantities of heterogeneous, patient-level information, the AI-based approach is progressively fostering the growth of a data-driven paradigm to complement traditional, hypothesis-driven clinical research. However, the development of reliable AI models requires access to large, high-quality, and continuously updated datasets. Despite this necessity, no infrastructure currently exists to enable federated, multi-omic, standardized, prospective, and large-scale collection and analysis of real-world clinical and biological data in the context of lung cancer. We established the APOLLO11 consortium, a distributed, nationwide, updated Italian lung cancer network designed to build a decentralized, long-term, population-based, real-world data repository and a multilevel biobank, locally stored and centrally annotated. This strategy seeks to lay the foundation for the clinical implementation of data-driven research, ultimately advancing precision oncology.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer

  • Arsela Prelaj,
  • Leonardo Provenzano,
  • Vanja Miskovic,
  • Monica Ganzinelli,
  • Laura Mazzeo,
  • Maria Gemelli,
  • Cecilia Silvestri,
  • Andrea Spagnoletti,
  • Rebecca Romanò,
  • Marta Brambilla,
  • Mario Occhipinti,
  • Teresa Beninato,
  • Paolo Ambrosini,
  • Elisa Sottotetti,
  • Margherita Favali,
  • Aleksandra Zec,
  • Alberto Ferrarin,
  • Giulia Corrao,
  • Marco Meazza Prina,
  • Margherita Ruggirello,
  • Moreno Bruno Marino,
  • Andra Diana Dumitrascu,
  • Rosa Maria Di Mauro,
  • Claudia Giani,
  • Chiara Cavalli,
  • Roberta Serino,
  • Chiara Catania,
  • Antonella Panzardi,
  • Giulio Metro,
  • Chiara Bennati,
  • Roberto Ferrara,
  • Marianna Macerelli,
  • Alberto Servetto,
  • Maria Silvia Cona,
  • Nicla La Verde,
  • Luca Toschi,
  • Paolo Baili,
  • Federica Corso,
  • Emanuela Zito,
  • Saverio Cinieri,
  • Rossana Berardi,
  • Giovanni Scoazec,
  • Alessandro Inno,
  • Stefania Gori,
  • Salvatore Pisconti,
  • Federica Buzzacchino,
  • Matteo Brighenti,
  • Federica Biello,
  • Alfredo Tartarone,
  • Giancarlo Pruneri,
  • Antonino Belfiore,
  • Luca Agnelli,
  • Alessandro Guidi,
  • Luca Invernizzi,
  • Noemi Salmistraro,
  • Andrea Riccardo Filippi,
  • Piergiorgio Solli,
  • Giulia Galli,
  • Daniele Lorenzini,
  • Elio Gregory Pizzutilo,
  • Filippo De Braud,
  • Alessandra Pedrocchi,
  • Francesco Trovò,
  • Carlo Genova,
  • Carminia Maria Della Corte,
  • Giuseppe Viscardi,
  • Marina Chiara Garassino,
  • Alessio Cortellini,
  • Emanuele Mingo,
  • Marco Russano,
  • Diego Signorelli,
  • Claudia Proto,
  • Andrea Vingiani,
  • Sabina Sangaletti,
  • Giuseppe Lo Russo,
  • Giorgia Di Liberti,
  • Claudia Agosta,
  • Ghazal Farhikhteh,
  • Daniela Miliziano,
  • Giorgia Corbo,
  • Beshoy Guirges,
  • Cristina Licciardello,
  • Lorenzo Antonuzzo,
  • Francesco Verderame,
  • Giulia Barletta,
  • Gianpaolo Spinelli,
  • Rita Chiari,
  • Rita Emili,
  • Federica Bertolini,
  • Grisanti Salvatore,
  • Emanuele Vita,
  • Chiara Bonalume,
  • Michele Aieta,
  • Luigi Lacriola,
  • Michele Borraccino,
  • Claudia Bareggi,
  • Fabrizio Citarella,
  • Giovanni Apolone,
  • Silvia Taverna,
  • Antonio Lugini,
  • Cesare Fattoi,
  • Alfonso Marchianò,
  • Alessandro Leonetti

摘要

Identifying predictive and resistance biomarkers remains one of the most relevant unmet needs in clinical cancer research. Artificial Intelligence (AI) represents a powerful tool to develop predictive algorithms tailored to individual patients. Thanks to its ability to process large quantities of heterogeneous, patient-level information, the AI-based approach is progressively fostering the growth of a data-driven paradigm to complement traditional, hypothesis-driven clinical research. However, the development of reliable AI models requires access to large, high-quality, and continuously updated datasets. Despite this necessity, no infrastructure currently exists to enable federated, multi-omic, standardized, prospective, and large-scale collection and analysis of real-world clinical and biological data in the context of lung cancer. We established the APOLLO11 consortium, a distributed, nationwide, updated Italian lung cancer network designed to build a decentralized, long-term, population-based, real-world data repository and a multilevel biobank, locally stored and centrally annotated. This strategy seeks to lay the foundation for the clinical implementation of data-driven research, ultimately advancing precision oncology.